JP2018509470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509470A5 JP2018509470A5 JP2018501141A JP2018501141A JP2018509470A5 JP 2018509470 A5 JP2018509470 A5 JP 2018509470A5 JP 2018501141 A JP2018501141 A JP 2018501141A JP 2018501141 A JP2018501141 A JP 2018501141A JP 2018509470 A5 JP2018509470 A5 JP 2018509470A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- amount
- fexofenadine
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 229960003592 fexofenadine Drugs 0.000 claims 8
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 8
- 229960003940 naproxen sodium Drugs 0.000 claims 7
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 claims 7
- 239000000739 antihistaminic agent Substances 0.000 claims 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 229940124623 antihistamine drug Drugs 0.000 claims 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- -1 ketorofen Chemical compound 0.000 claims 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 3
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 3
- 229960001803 cetirizine Drugs 0.000 claims 3
- 229960001271 desloratadine Drugs 0.000 claims 3
- 229960001680 ibuprofen Drugs 0.000 claims 3
- 229960003088 loratadine Drugs 0.000 claims 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960000616 diflunisal Drugs 0.000 claims 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 2
- 229960005293 etodolac Drugs 0.000 claims 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 229960004752 ketorolac Drugs 0.000 claims 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 2
- 229960001929 meloxicam Drugs 0.000 claims 2
- 229960004270 nabumetone Drugs 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- 229960002702 piroxicam Drugs 0.000 claims 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
- 229960000953 salsalate Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 229960000894 sulindac Drugs 0.000 claims 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
- 229960001017 tolmetin Drugs 0.000 claims 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229940112822 chewing gum Drugs 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000035922 thirst Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138665P | 2015-03-26 | 2015-03-26 | |
| US62/138,665 | 2015-03-26 | ||
| PCT/US2016/023200 WO2016154028A1 (en) | 2015-03-26 | 2016-03-18 | Methods and compositions to inhibit symptoms associated with veisalgia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509470A JP2018509470A (ja) | 2018-04-05 |
| JP2018509470A5 true JP2018509470A5 (enExample) | 2019-05-09 |
| JP6851365B2 JP6851365B2 (ja) | 2021-03-31 |
Family
ID=56976188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501141A Active JP6851365B2 (ja) | 2015-03-26 | 2016-03-18 | 宿酔に伴う症状を抑制するための方法及び組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10420756B2 (enExample) |
| EP (2) | EP3973957A1 (enExample) |
| JP (1) | JP6851365B2 (enExample) |
| KR (1) | KR102597910B1 (enExample) |
| CN (2) | CN107635549A (enExample) |
| AU (1) | AU2016235484B2 (enExample) |
| BR (1) | BR112017020307B1 (enExample) |
| CA (1) | CA2980162C (enExample) |
| ES (1) | ES2926494T3 (enExample) |
| IL (1) | IL254641B2 (enExample) |
| MX (2) | MX390011B (enExample) |
| NZ (1) | NZ735777A (enExample) |
| PL (1) | PL3273952T3 (enExample) |
| WO (1) | WO2016154028A1 (enExample) |
| ZA (1) | ZA201706794B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635549A (zh) | 2015-03-26 | 2018-01-26 | 杰奎琳·M·艾弗森 | 抑制与宿醉相关的症状的方法和组合物 |
| WO2018232260A1 (en) | 2017-06-16 | 2018-12-20 | SEN-JAM Pharmaceutical LLC | Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections |
| WO2019046201A1 (en) * | 2017-08-30 | 2019-03-07 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION |
| WO2019055941A1 (en) * | 2017-09-18 | 2019-03-21 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING OPIOID DEPENDENCE |
| WO2019055942A1 (en) * | 2017-09-18 | 2019-03-21 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE |
| WO2019055939A1 (en) * | 2017-09-18 | 2019-03-21 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING SYMPTOMS ASSOCIATED WITH OPIOID WEANING |
| WO2019178516A1 (en) * | 2018-03-16 | 2019-09-19 | SEN-JAM Pharmaceutical LLC | Methods and compositions to treat enteropathic arthritis |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4075426A (en) | 1976-03-12 | 1978-02-21 | Harvey Mitchell Gould | Parallel silent communicator |
| US4496548A (en) * | 1983-02-04 | 1985-01-29 | Moldowan Mervin J | Composition and method for reducing hangover |
| US5053396A (en) | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
| US4975426A (en) * | 1987-06-08 | 1990-12-04 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| AU8764191A (en) | 1990-09-28 | 1992-04-28 | Mcneill-Ppc Inc. | Ibuprofen-antihistamine combinations |
| RU2167657C2 (ru) * | 1992-08-03 | 2001-05-27 | Сепракор, Инк. | Фармацевтическая композиция для лечения аллергических заболеваний, способ антигистаминного лечения, применение композиции для получения лекарственного препарата |
| DE69629989T2 (de) | 1995-04-21 | 2004-07-22 | Sekisui Kagaku Kogyo K.K. | Präparate zur äusserlichen anwendung zur behandlung von dermatosen |
| US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
| DE19708209C2 (de) | 1997-02-28 | 2000-03-02 | Hans Juergen Pauling | Wiederaufladbare Batterieanordnung und deren Verwendung |
| US20050281751A1 (en) | 1997-07-21 | 2005-12-22 | Bruce Levin | Directed intranasal administration of pharmaceutical agents |
| CN1278728A (zh) * | 1997-09-19 | 2001-01-03 | 普罗克特和甘保尔公司 | 治疗呼吸系统疾病的组合物和方法 |
| US6596770B2 (en) | 2000-05-05 | 2003-07-22 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| US20030181495A1 (en) | 1998-06-23 | 2003-09-25 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| US6697361B2 (en) | 1998-09-15 | 2004-02-24 | Nortel Networks Limited | Method and apparatus for stream aggregation in a multiprotocol label switching network environment |
| US6274627B1 (en) | 1999-10-12 | 2001-08-14 | Medinox, Inc. | Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor |
| WO2003009834A1 (en) | 2000-08-17 | 2003-02-06 | Battey Alyce S | Oral delivery of pharmaceuticals via encapsulation |
| US20020045184A1 (en) * | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
| US20050009730A1 (en) | 2001-10-16 | 2005-01-13 | Dale Edgar | Treatment of cns disorders using cns target modulators |
| US7189757B2 (en) | 2001-10-16 | 2007-03-13 | Hypnion, Inc. | Treatment of sleep disorders using CNS target modulators |
| GB0128674D0 (en) | 2001-11-30 | 2002-01-23 | Boots Co Plc | Treatment of sleep disorders and the like |
| AU2003210598A1 (en) | 2002-01-18 | 2003-09-04 | Hypnion Inc | Treatment of sleep disorders using sleep target modulators |
| DE10223147A1 (de) * | 2002-05-16 | 2003-11-27 | Newfrey Llc | Fügesystemkopf, Fügesystem und Verfahren zum Zuführen und Fügen von Elementen |
| WO2004016268A1 (en) * | 2002-08-15 | 2004-02-26 | Tan Oon T | Composition and method for controlling alcohol-induced facial flushing in susceptible humans |
| US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| US20040253311A1 (en) * | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| TWI313598B (en) * | 2002-12-18 | 2009-08-21 | Wyeth Corp | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
| GB0312425D0 (en) | 2003-05-30 | 2003-07-09 | Boots Co Plc | Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith |
| GB0312419D0 (en) | 2003-05-30 | 2003-07-02 | Boots Healthcare Int Ltd | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
| US20070292498A1 (en) | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| US20110053999A1 (en) | 2004-03-03 | 2011-03-03 | Daley Thomas E | 4-methylpyrazole formulations for inhibiting ethanol intolerance |
| US20080021083A1 (en) * | 2004-03-03 | 2008-01-24 | Daley Thomas E | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance |
| GB2435410B (en) * | 2004-04-21 | 2007-12-05 | Silent Gliss Internat Ltd | Improvements in or relating to curtain heading systems |
| ATE529133T1 (de) | 2004-08-18 | 2011-11-15 | Medrx Co Ltd | Topisches präparat |
| US20060063754A1 (en) | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| EP1804804B1 (en) | 2004-09-21 | 2012-01-25 | Hypnion, Inc. | 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS |
| US7563785B2 (en) | 2004-10-29 | 2009-07-21 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
| WO2006064747A1 (ja) | 2004-12-15 | 2006-06-22 | Saitama Daiichi Pharmaceutical Co., Ltd. | 医療用テープ剤 |
| ES2510690T3 (es) | 2004-12-17 | 2014-10-21 | Alan B. Cash | Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad |
| CA2597525A1 (en) | 2005-02-17 | 2006-08-24 | Senju Pharmaceutical Co., Ltd. | Solid ophthalmic drug for external use |
| US20070093520A1 (en) | 2005-04-15 | 2007-04-26 | Caras Steven D | Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject |
| US20070086974A1 (en) * | 2005-10-06 | 2007-04-19 | Gawande Rahul S | Cetirizine compositions |
| US20070196518A1 (en) | 2005-12-15 | 2007-08-23 | Karol Wojewnik | Composition and Method for Mitigating a Negative Effect of Alcohol Consumption |
| WO2007092334A1 (en) | 2006-02-02 | 2007-08-16 | Hypnion, Inc. | Method of treating sleep disorders |
| WO2007092333A1 (en) | 2006-02-03 | 2007-08-16 | Hypnion, Inc. | Use of olopatadine for treating sleep disorders |
| GB2435418A (en) | 2006-02-28 | 2007-08-29 | Amalan Selvarajah | Composition for preventing and alleviating alcohol hangover |
| US20070224128A1 (en) | 2006-03-07 | 2007-09-27 | Donn Michael Dennis | Drug adherence monitoring system |
| US20080131532A1 (en) | 2006-10-17 | 2008-06-05 | Lorn Leitman | Fast asleep |
| MX2009004439A (es) * | 2006-10-25 | 2009-05-11 | Mcneil Ppc Inc | Composicion de ibuprofeno. |
| MX2009006672A (es) | 2006-12-19 | 2009-10-26 | Univ Virginia | Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol. |
| WO2008095086A2 (en) | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| JP2010537990A (ja) | 2007-08-27 | 2010-12-09 | ユニバーシティ オブ バージニア パテント ファウンデーション | アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ |
| US20090156982A1 (en) | 2007-09-06 | 2009-06-18 | Arezou Petrie | Transdermal treatment device and method |
| MX2010004265A (es) | 2007-10-19 | 2010-07-28 | Innozen Inc | Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo. |
| EP3090739A1 (en) * | 2008-01-04 | 2016-11-09 | Schabar Research Associates LLC | Compositions composed of naproxen sodium and nizatidine |
| WO2009094177A1 (en) * | 2008-01-24 | 2009-07-30 | Raptor Therapeutics Inc. | Protopanaxadiol-type ginsenoside compositions and uses thereof |
| US20090258869A1 (en) | 2008-02-08 | 2009-10-15 | The Regents Of The University Of California | Methods and compounds for treatment or prevention of substance-related disorders |
| KR20100127799A (ko) | 2008-02-28 | 2010-12-06 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 세로토닌 운반체 유전자 및 알콜중독의 치료 |
| KR20110017365A (ko) * | 2008-05-30 | 2011-02-21 | 페어필드 클리니컬 트라이얼즈 엘엘씨 | 피부 염증 및 변색을 위한 방법 및 조성물 |
| AU2009260166B2 (en) | 2008-06-20 | 2014-10-09 | Alphapharm Pty Ltd | Pharmaceutical formulation |
| US20130029970A1 (en) | 2009-07-10 | 2013-01-31 | Ironwood Pharmaceuticals, Inc | CB Receptor Agonists |
| WO2011006073A1 (en) | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| US20130109721A1 (en) | 2009-12-08 | 2013-05-02 | Ironwood Pharmaceuticals, Inc. | FAAH Inhibitors |
| JP6200648B2 (ja) | 2009-12-18 | 2017-09-20 | アケリオス セラピューティクス，インコーポレーテッド | 三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための組成物 |
| WO2011100359A1 (en) | 2010-02-09 | 2011-08-18 | Ironwood Pharmaceuticals, Inc. | Cannabinoid agonists |
| US20130196960A1 (en) | 2010-02-09 | 2013-08-01 | Ironwood Pharmaceuticals, Inc. | Cannabinoid Receptor Agonists |
| WO2012048294A2 (en) | 2010-10-07 | 2012-04-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
| WO2012088431A1 (en) | 2010-12-23 | 2012-06-28 | Ironwood Pharmaceuticals, Inc. | Faah inhibitors |
| EP2680828A4 (en) | 2011-02-28 | 2014-07-30 | Technologies Khlôros Inc | COUGAR MEANS FOR ORAL ABSORPTION |
| CN108014334B (zh) | 2011-05-20 | 2021-11-30 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| US9161957B2 (en) | 2012-08-03 | 2015-10-20 | Life Well Lived, Llc | Compositions and methods for reducing blood alcohol content |
| JP6276944B2 (ja) * | 2013-08-29 | 2018-02-07 | 興和株式会社 | フェキソフェナジンとｎｓａｉｄ含有医薬組成物 |
| US20150132410A1 (en) * | 2013-11-14 | 2015-05-14 | Michael M. Jacobs | Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome |
| CN107635549A (zh) | 2015-03-26 | 2018-01-26 | 杰奎琳·M·艾弗森 | 抑制与宿醉相关的症状的方法和组合物 |
| WO2019178516A1 (en) * | 2018-03-16 | 2019-09-19 | SEN-JAM Pharmaceutical LLC | Methods and compositions to treat enteropathic arthritis |
-
2016
- 2016-03-18 CN CN201680030862.6A patent/CN107635549A/zh active Pending
- 2016-03-18 CA CA2980162A patent/CA2980162C/en active Active
- 2016-03-18 MX MX2017012132A patent/MX390011B/es unknown
- 2016-03-18 KR KR1020177031097A patent/KR102597910B1/ko active Active
- 2016-03-18 EP EP21208021.2A patent/EP3973957A1/en active Pending
- 2016-03-18 PL PL16769429.8T patent/PL3273952T3/pl unknown
- 2016-03-18 AU AU2016235484A patent/AU2016235484B2/en active Active
- 2016-03-18 WO PCT/US2016/023200 patent/WO2016154028A1/en not_active Ceased
- 2016-03-18 BR BR112017020307-3A patent/BR112017020307B1/pt active IP Right Grant
- 2016-03-18 IL IL254641A patent/IL254641B2/en unknown
- 2016-03-18 NZ NZ735777A patent/NZ735777A/en unknown
- 2016-03-18 US US15/074,524 patent/US10420756B2/en active Active
- 2016-03-18 CN CN202211634942.6A patent/CN115887456A/zh active Pending
- 2016-03-18 EP EP16769429.8A patent/EP3273952B1/en active Active
- 2016-03-18 JP JP2018501141A patent/JP6851365B2/ja active Active
- 2016-03-18 ES ES16769429T patent/ES2926494T3/es active Active
-
2017
- 2017-09-25 MX MX2022001796A patent/MX2022001796A/es unknown
- 2017-10-09 ZA ZA2017/06794A patent/ZA201706794B/en unknown
-
2019
- 2019-09-17 US US16/573,384 patent/US11464766B2/en active Active
-
2022
- 2022-09-02 US US17/902,124 patent/US20230064685A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601529A (en) | Tapentadol compositions | |
| AR076540A1 (es) | Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor | |
| AR082091A1 (es) | Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion | |
| McCarberg et al. | Evolving therapeutic strategies to improve nonsteroidal anti-inflammatory drug safety | |
| MA29115B1 (fr) | Produits pharmaceutiques solides, administres par voie orale et contenant du rivaroxaban, a liberation modifiee | |
| JP2013509444A5 (enExample) | ||
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| IL194885A0 (en) | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid | |
| Moore | In search of an ideal analgesic for common acute pain | |
| UY33061A (es) | Composiciones para comprimidos desintegrables oralmente de ondansetrón para prevenir náuseas y vómitos | |
| IL254641B2 (en) | Methods and compositions comprising naproxen and fexofenadine to inhibit symptoms of dizziness associated with intake of alcohol | |
| WO2019055942A4 (en) | Methods and compositions to inhibit tolerance to opioids | |
| AR054595A1 (es) | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis | |
| BR112013012100A2 (pt) | composição ou formulação farmacêutica adaptada para administração oral em forma de comprimido, comprimido revestido ou cápsula na prevenção ou tratamento de distúrbios intestinais, processo para preparar a composição ou formulação farmacêutica e uso da composição ou formulação farmacêutica | |
| DK2853262T3 (en) | Treatment of sunburn using analgesics and antihistamines | |
| CL2013003176A1 (es) | Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol. | |
| UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
| BRPI0809310A2 (pt) | Composição farmacêutica em forma de um comprimido sublingual que compreende um anti-inflamatório não esteroidal e um análgésico opiáceo para o controle da dor. | |
| Manohar et al. | Prescribing pattern of gastroprotective agents with non-steroidal anti-inflammatory drugs | |
| US20150290174A1 (en) | Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine | |
| ES2526359T3 (es) | Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos | |
| CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
| ECSP088801A (es) | Composicion farmaceutica que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia | |
| ECSP11010999A (es) | Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina | |
| RU2012102980A (ru) | Лекарственное средство для длительного применения nsaid |